Tempus AI and Pathos AI Sign Neurology Data Deal Worth Up to $55 Million

Tempus AI and Pathos AI agreed to a five-year neurology data deal worth up to $55 million, giving Pathos access to as many as 500,000 de-identified records for drug research.

Pathos announced collaborations with Bristol Myers Squibb and Tempus on Friday, Oct. 23, one day after Tempus and Pathos signed the neurology order form.

Under the agreement, Tempus will use commercially reasonable efforts to license Pathos 500,000 de-identified records of people with Alzheimer’s disease or other specified neurological conditions. The target pace is 100,000 records a year for five years.

Pathos will pay $100 for each delivered record, up to $50 million, plus $5 million for the availability of record updates. The data-license fees will depend on how many records Tempus delivers. Data-license fees are invoiced monthly, while the update fee is invoiced quarterly.

Pathos plans to analyze the longitudinal data through Foundry, its AI platform, to test hypotheses about disease biology and inform clinical-trial design. The dataset is intended to track patient outcomes over time. Tempus also licensed Pathos an agentic analysis tool. The license permits Pathos to use the data and tool in its research and support Bristol Myers Squibb’s drug development; the side letter confirms the drugmaker’s sublicense rights.

Bristol Myers Squibb gets Foundry access across its broader portfolio, plus three years of exclusive rights for its neuroscience development programs.

“Making meaningful progress against a disease as devastating as Alzheimer’s requires unprecedented data scale and computing power,” said Eric Lefkofsky, Tempus’ founder and CEO.

Tempus applied its related-person transaction policy to the Pathos deals, citing overlap in executives and equity ownership. A special committee of disinterested Tempus directors reviewed and approved the order form and side letter.

The neurology agreement is separate from a Bristol Myers Squibb-Tempus oncology data and services agreement, which provides $137.5 million in fixed payments through Dec. 31, 2031. If the neurology deal reaches its $55 million cap, the two agreements would total $192.5 million in payments to Tempus over about five years.

Pathos also announced a $237 million Series E financing at a post-money valuation of about $3 billion.